Publications

5891 Results

No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404.

Authors
Othus M;Truong TG;Sharon E;Kendra K;Grossman K;Buchbinder E;Khushalani N;Eroglu Z;Chandra S;Doolittle GC;Kirkwood JM;Johnson D;Taylor M;Sondak VK;Ribas A;Patel SP
Journal / Conference
AACR Immuno-Oncology Conference (February 18-21, 2026, Los Angeles, CA); Oral LB-B005
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1404

Inflammatory spatial niches distinguished by antigen presentation and interferon response programs explain the high immune response rate of desmoplastic melanoma: Comparison of biopsies from SWOG S1512 and S1616.

Authors
Chen DG
Journal / Conference
AACR Immuno-Oncology Conference (February 18-21, 2026, Los Angeles, CA); Abstract B038
Year
2026
Research Committee(s)
Melanoma
Study Number(s)
S1512, S1616

SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).

Authors
Svatek RS;Tangen CM;Meeks JJ;Gilbert SM;Lotan Y;Tyson M;Crispen P;Delacroix SE;Gills J;Daneshmand S;Woods M;Master VA;Mark JR;Alva AS;Bangs R;Nakagawa D;Unger JM;Plets M;Thompson IM;Lerner SP
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); LBA629
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S1602

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.

Authors
Sadeghi S
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS894
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S1937

SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).

Authors
Ballas LK
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS913
Year
2026
Research Committee(s)
Genitourinary
Study Number(s)
S2427

ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).

Authors
Kilari D
Journal / Conference
ASCO GU Symposium (February 26-28, 2026); TPS290
Year
2026
Research Committee(s)
Genitourinary

Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405.

Authors
Soni S
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 1011
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels.

Authors
Trujillo SS
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 6751
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Associations of WCRF/AICR recommendations with survival and chemotherapy outcomes in colon cancer: CALGB/SWOG 80702 (Alliance).

Authors
Cheng E
Journal / Conference
AACR Annual Meeting 2026 (April 17-22, 2026, San Diego, CA); Abstract 5038
Year
2026
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

SWOG S1823/CCTG GCC-01 secondary use of data: North American patterns of care in clinical stage I germ cell tumours.

Authors
Coulombe AM;Ozgun G;Colby S;King J;Neuhouser ML;Zell JA;Arun B;Daneshmand S;Harzstark A;Arnold KB;Kollmannsberger CK;Nichols CR;Nappi L
Journal / Conference
2026 ASCO Genitourinary Cancers Symposium, San Francisco February 28, 2026; poster 622
Year
2026
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1823